Caris Life Sciences, Inc. (CAI) Stock
CAI Key Statistics
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
CEO: David Dean Halbert. Company website
CAI — Frequently Asked Questions
What is the CAI stock price today?
Caris Life Sciences, Inc. (CAI) trades at $29.98, down 3.04% on the day, as of Sep 20, 2026 14:57 UTC.
What is Caris Life Sciences, Inc.'s market cap?
Caris Life Sciences, Inc. has a market capitalisation of $8.47B, calculated from the live CAI share price and shares outstanding.
What is the P/E ratio of CAI?
CAI trades at a trailing P/E of 83.28, from earnings per share of $0.36 over the last twelve months.
How much revenue does Caris Life Sciences, Inc. make?
Caris Life Sciences, Inc. generated revenue of $989.61M over the trailing twelve months, which puts the stock at 8.56 times sales.
What is the 52-week range for CAI?
CAI has traded between $14.19 and $34.54 over the past 52 weeks, and the last price is 13.2% below that high.
Is Caris Life Sciences, Inc. profitable?
Yes. Caris Life Sciences, Inc. keeps 10.62% of revenue as net income over the trailing twelve months.
What is the analyst price target for CAI?
Wall Street analysts rate CAI Buy, with an average price target of $26.00, 13.3% below the current price.
What sector is Caris Life Sciences, Inc. in?
Caris Life Sciences, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Caris Life Sciences, Inc.?
David Dean Halbert is the chief executive of Caris Life Sciences, Inc., which employs 1,846 people.
Where can I track CAI in real time?
QFI Terminal shows CAI with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See CAI live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open CAI in Terminal See plans